enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Stem cell therapy for macular degeneration - Wikipedia

   en.wikipedia.org/wiki/Stem_cell_therapy_for...

   Induced pluripotent stem cell taken from blood cell and converted in retinal pigment epithelium. Stem cell therapy for macular degeneration is an emerging treatment approach aimed at restoring vision in individuals suffering from various forms of macular degeneration, particularly age-related macular degeneration (AMD). [1]

3. FDA Approves Biosimilars for Macular Degeneration Treatment - AOL

   www.aol.com/lifestyle/fda-approves-biosimilars...

   The FDA approved two interchangeable biosimilars to treat macular degeneration. The biosimilars work the same way as Eylea which prevents abnormal blood vessel growth in the eye and helps preserve ...

4. Gene therapy of the human retina - Wikipedia

   en.wikipedia.org/wiki/Gene_therapy_of_the_human...

   Following the successful clinical trials in LCA, researchers have been developing similar treatments using adeno-associated virus for age-related macular degeneration (AMD). To date, efforts have focused on long-term delivery of VEGF inhibitors to treat the wet form of macular degeneration. Whereas wet AMD is currently treated using frequent ...

5. Retinal implant - Wikipedia

   en.wikipedia.org/wiki/Retinal_implant

   A retinal implant is a visual prosthesis for restoration of sight to patients blinded by retinal degeneration. The system is meant to partially restore useful vision to those who have lost their photoreceptors due to retinal diseases such as retinitis pigmentosa (RP) or age-related macular degeneration (AMD).

6. Macular degeneration - Wikipedia

   en.wikipedia.org/wiki/Macular_degeneration

   The incidence of age-related macular degeneration and its associated features increases with age and is low in people <55 years of age. [101] Smoking is the strongest modifiable risk factor. [102] As of 2008, age-related macular degeneration accounts for more than 54% of all vision loss in the white population in the US. [103]

7. Conbercept - Wikipedia

   en.wikipedia.org/wiki/Conbercept

   Conbercept, sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) [1] [2] and diabetic macular edema (DME). [3] The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 2013.